4 104 183
www.stocktitan.net
Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Caris Life Sciences (Nasdaq: CAI) reported second quarter 2026 revenue of $263.7 million, up 45% year over year, driven mainly by $252.3 million in molecular profiling services revenue. The company completed approximately 59,200 clinical cases, up about 18%, and delivered a gross margin of 68%, roughly 500 bps higher than a year earlier.Net loss narrowed to $0.6 million, with positive Adjusted EBITDA of $55.7 million, operating cash flow of $28.5 million and free cash flow of $6.4 million. Caris raised its 2026 revenue guidance to $1.03–$1.04 billion, implying 27%–28% growth, and reaffirmed clinical therapy selection volume growth of about 20%. The company also highlighted multiple product launches, MolDX approval for Caris ChromoSeq, a dual listing on NYSE Texas, and an authorized share repurchase program of up to $100 million, with approximately $82.1 million remaining.
